Phase 2 Endometrial Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People aged 18 years or older.
• People who have cervical cancer that has come back or spread to other parts of the body, confirmed by a tissue or cell sample.
• People who have already received treatment with a medicine called pembrolizumab (either alone or combined with other treatments) for at least 6 weeks.
• People whose cervical cancer has tested positive for HPV (Human Papillomavirus), confirmed by a tissue or cell sample.
• People who have at least one area of cancer that can be measured using standard imaging guidelines (called RECIST v1.1).
• People who are reasonably active and able to care for themselves, rated 0 or 1 on a standard health and activity scale (confirm with trial site).
• People who are expected to live for at least 12 weeks from the time of joining the trial.
• People whose liver, kidneys, and other organs are working well enough (confirm with trial site for specific requirements).
• Women who could become pregnant must have a negative pregnancy blood test before starting, and must agree to use reliable contraception during the trial and for at least 6 months after finishing treatment.
• People who are able to understand the trial information and are willing to sign a consent form.

Who may not be able to join:

• People who have had chemotherapy or targeted therapy within the last 14 days, or a monoclonal antibody treatment within the last 4 weeks, or who still have unresolved side effects from previous treatments.
• People with a weakened immune system, an active autoimmune disease being treated with immune-suppressing medicines, or who have taken immune-suppressing medicines within the last 7 days. (People with HIV may still be considered if their condition is well controlled — confirm with trial site.)
• People who have had active Hepatitis B or Hepatitis C infection within 30 days before joining.
• People with a history of lung inflammation or scarring of the lungs that was not caused by an infection.
• People with a history of autoimmune diseases affecting hormone-producing glands — with exceptions for people who have been successfully treated for Graves' disease, or who have an underactive thyroid managed with replacement medication (confirm with trial site).
• People who have received a live vaccine within 30 days before the first dose.
• People who have had another active cancer within the past year.
• People who have a known cancer affecting the brain or central nervous system.
• People who have had a severe allergic reaction (Grade 3 or higher) to pembrolizumab or any of its ingredients.
• People with a known history of active tuberculosis (TB).
• People who are pregnant or breastfeeding.
• People who have had a solid organ transplant (such as a kidney, liver, or heart transplant).
• People who are currently taking part in another clinical trial involving an experimental treatment or device, or who have done so within the last 4 weeks.
• People who, in the opinion of the trial doctor, may have difficulty following the trial's monitoring and visit requirements.

Important: Always verify eligibility with the trial site directly before applying.